News Headlines Article

House Dems question Gilead’s HIV drug donations
Modern Healthcare

Democratic members of the House Oversight Committee want Gilead Sciences to reveal whether its decision to donate more than 2 million doses of its HIV-prevention medication Truvada was connected to an ongoing patent dispute.

In a letter sent Wednesday to Gilead CEO Daniel O’Day, House Oversight and Reform Committee Chair Rep. Elijah Cummings (D-Md.) asked whether the company’s decision to donate Truvada was in some way connected to the company’s dispute over its patent for the drug.